These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 19040304)

  • 1. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio.
    Rauner M; Stupphann D; Haas M; Fert I; Glatigny S; Sipos W; Breban M; Pietschmann P
    J Rheumatol; 2009 Jan; 36(1):120-6. PubMed ID: 19040304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway.
    Franklin M; Bu SY; Lerner MR; Lancaster EA; Bellmer D; Marlow D; Lightfoot SA; Arjmandi BH; Brackett DJ; Lucas EA; Smith BJ
    Bone; 2006 Dec; 39(6):1331-42. PubMed ID: 16890505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased bone strength in HLA-B27 transgenic rat model of spondyloarthropathy.
    Akhter MP; Jung LK
    Rheumatology (Oxford); 2007 Aug; 46(8):1258-62. PubMed ID: 17526927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells from spondylarthritis-prone HLA-B27-transgenic rats display altered cytoskeletal dynamics, class II major histocompatibility complex expression, and viability.
    Dhaenens M; Fert I; Glatigny S; Haerinck S; Poulain C; Donnadieu E; Hacquard-Bouder C; André C; Elewaut D; Deforce D; Breban M
    Arthritis Rheum; 2009 Sep; 60(9):2622-32. PubMed ID: 19714626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
    Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
    Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet.
    Zhang Y; Dong XL; Leung PC; Wong MS
    Bone; 2009 Jan; 44(1):46-52. PubMed ID: 18848653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN beta2-microglobulin-transgenic rat lines.
    Fert I; Glatigny S; Poulain C; Satumtira N; Dorris ML; Taurog JD; Breban M
    Arthritis Rheum; 2008 Nov; 58(11):3425-9. PubMed ID: 18975325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
    Wang J; Gao H; Wang K; Li W; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Jul; 23(7):777-80. PubMed ID: 19662974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA; Malaponte G; Pennisi P; Li Volti G; Trovato G; Mangiafico M; Bevelacqua Y; Mazza F; Fiore CE
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
    Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
    J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
    Wang J; Wang K; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.